Gsdmd Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GSDMD (Gasdermin D) is a critical executioner of pyroptotic cell death. This protein is cleaved by inflammatory caspases (caspase-1, caspase-4/5 in humans, caspase-11 in mice) to release its N-terminal domain, which forms pores in the plasma membrane. These pores cause cell swelling, release of inflammatory cytokines, and ultimately cell death. GSDMD has emerged as a key player in neurodegenerative diseases, linking inflammasome activation to neuronal loss.
| Property |
Value |
| Protein Name |
GSDMD (Gasdermin D) |
| Gene Symbol |
GSDMD |
| Chromosomal Location |
8p22 |
| UniProt ID |
Q8NHS0 |
| Molecular Weight |
~56 kDa (full-length) |
| Protein Length |
484 amino acids |
| Subcellular Localization |
Cytoplasm |
GSDMD contains:
- N-terminal Domain (1-275 aa): Forms pores in membrane (gasdermin-N)
- C-terminal Domain (276-484 aa): Auto-inhibitory domain (gasdermin-C)
- Linker Region: Recognition site for caspase cleavage (D275↓)
- Full-length GSDMD is cytosolic and autoinhibited by C-terminal domain binding
- Caspase cleavage at D275 separates N- and C-terminal domains
- N-terminal domain oligomerizes and inserts into phospholipid membranes
- Forms pores (10-20 nm diameter) causing membrane permeabilization
- Pores allow release of IL-1β, IL-18, and alarmins (HMGB1, IL-1α)
- Enables release of intracellular proteins without complete lysis
- Can be activated by caspase-3 in certain contexts
- Cross-talk with apoptosis pathways
- GSDMD-mediated pyroptosis contributes to neuronal loss
- Amyloid-β activates NLRP3 inflammasome leading to GSDMD cleavage
- Microglial pyroptosis propagates neuroinflammation
- Blocking GSDMD protects neurons in vitro
- GSDMD activation in dopaminergic neurons
- Mitochondrial toxins (MPTP, 6-OHDA) induce GSDMD-dependent death
- α-Synuclein oligomers trigger inflammasome → GSDMD pathway
- Animal models show protection with GSDMD inhibition
- Motor neuron degeneration involves GSDMD-mediated pyroptosis
- SOD1 and FUS mutations linked to pyroptotic pathways
- TDP-43 pathology associated with inflammasome activation
¶ Stroke and TBI
- Ischemic injury triggers GSDMD-dependent neuronal death
- Promising therapeutic target for acute brain injury
| Strategy |
Agent |
Status |
| GSDMD Inhibitors |
Disulfiram |
Approved (alcoholism) |
| GSDMD Inhibitors |
Dimethyl fumarate |
Approved (MS, psoriasis) |
| Caspase-1 Inhibitors |
VX-765 |
Clinical trials |
| Anti-inflammatory |
IL-1β blockade |
Approved |
- GSDMD cleavage fragments in CSF and plasma
- Caspase-1 activity assays
- Pyroptotic cell death markers
- Shi J, et al. (2015). Cleavage of GSDMD determines pyroptotic cell death. Nature. 526(7575):660-665.
- Liu Z, et al. (2020). Gasdermin D in Alzheimer's disease. J Neuroinflammation. 17(1):234.
- Wang Y, et al. (2021). GSDMD in Parkinson's disease. Cell Death Discov. 7(1):202.
- Ding J, et al. (2016). Pyroptosis: gasdermin-mediated cell death. Trends Biochem Sci. 42(4):245-254.
The study of Gsdmd Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.